FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at ASNC2016
FluoroPharma Medical Inc., will present the first comparative data from its Phase II trial of CardioPET in subjects with a high likelihood of coronary artery disease at ASNC2016 in Boca Raton, Fla. ASNC Past President and study author Gary Heller, MD, MASNC, will present the data at ASNC on Sept. 24. He performed the analysis of the SPECT and PET images with the clinical investigators, who acquired the image data at four sites in Belgium.After scoring the SPECT and PET images in accordance with ASNC standards, the data were compared to clinically indicated angiography for each subject who received imaging. Manuel Cerqueira, MD, MASNC, who was instrumental in defining the scoring standard, is a co-author of the study.
“We are excited that imaging data from this trial was accepted for presentation at such a prestigious forum as ASNC,” said the FluoroPharma Medical's Vice-President of Development, Edward Lyons. “This is an important step in understanding the unique clinical potential for PET-based fatty acid imaging in patients with coronary disease.”